The company intends to use the net proceeds to repay at maturity or redeem its $800 million aggregate principal amount of senior notes due in 2020.
The offering consists of two tranches, $400 million of 2.3 percent senior notes due 2024 and $650 million of 2.95 percent senior notes due 2029.
The firm said that it will use proceeds from the sale to purchase or repay other notes or loans, including up to $300 million in outstanding senior notes.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.
The company plans to use the financing to fund part of its 21.4 billion pending acquisition of GE Biopharma.
The firm will offer €4.4 billion of euro-denominated notes and $900 million in dollar-denominated notes. It will redeem another $4.5 billion in outstanding notes.
The firm said that on Oct. 13 it will redeem all of its outstanding 5 percent unsecured notes due in 2021.
Thermo Fisher Scientific said today that it plans to redeem two classes of senior notes later this month, with a total aggregate principal amount of $1.1 billion.
About $770 million in net proceeds will go toward the repayment of outstanding debt under its senior unsecured revolving credit facility.
The company said it will use the funds to repay the $75 million outstanding under its 2018 Note Purchase Agreement, to expand internationally, and on general operations.